Erlocip 150mg Tablet
Prescription Required
Marketed By
cipla pharma
Pack of
30 tablet
Salt Composition
Erlotinib
Storage
Keep in cold place
₹5590₹8908.18
37.25% Off
Inclusive of all taxes
1
Erlocip 150mg Tablet
Delivering To: —
All Substitutes
Overview
Erlocip 150mg Tablet is a prescription-based anticancer medicine. It is used for the treatment of pancreatic cancer and non-small cell lung cancer. This tablet has a salt constituent called 'Erlotinib,' which belongs to the drug class of 'kinase inhibitors. It stops the activity of the abnormal protein that leads to cancerous growth. Take it exactly as prescribed at the fixed time each day for better results.
Indication
non-small cell lung cancer (NSCLC) and pancreatic cancer
Side Effects
Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Erlocip 150mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:
Abdominal pain
Bone pain
Breathlessness
Constipation
Cough
Diarrhea
Fatigue
Fever
Infection
Muscle pain
Nausea
Rash
Stomatitis (Inflammation of the mouth)
Vomiting
Weight loss
Seek medical attention in case of any unusual or severe side effects immediately.
How To Use
The doctor determines the dosage and treatment duration with Erlocip 150mg Tablet as per the patient's health condition and stage of cancer. This tablet should be taken orally without food. Don't chew or crush the tablet. In the case of overdose, contact your doctor immediately.
Safety Advice
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking the Erlocip 150mg Tablet. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Erlocip 150mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition.
Breast Feeding
consult your doctor
Erlocip 150mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking an Erlocip 150mg Tablet, as you may feel dizzy.
Kidney
caution
Erlocip 150mg Tablet is safe for use in kidney disease if prescribed by the doctor. No dosage adjustment is necessary for this Tablet.
Liver
caution
Inform your doctor before starting the Erlocip 150mg Tablet if you have liver disease to avoid any serious side effects.
Missed Doses
If the patient misses a dose of medicine, skip it and continue with the normal schedule. No need to double the dose
Trusted Medicines, Delivered Worldwide
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Reference
1. Bonomi, P. (2003). Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert opinion on investigational drugs, 12(8), 1395-1401.
2. Kelley, R. K., & Ko, A. H. (2008). Erlotinib in the treatment of advanced pancreatic cancer. Biologics: targets and therapy, 2(1), 83-95.
3. Kelley, R. K., & Ko, A. H. (2008). Erlotinib in the treatment of advanced pancreatic cancer. Biologics: targets and therapy, 2(1), 83-95.
4. Liu, V., White, D. A., Zakowski, M. F., Travis, W., Kris, M. G., Ginsberg, M. S., ... & Azzoli, C. G. (2007). Pulmonary toxicity associated with erlotinib. Chest, 132(3), 1042-1044.
5. Scagliotti, G. V., Krzakowski, M., Szczesna, A., Strausz, J., Makhson, A., Reck, M., ... & Govindan, R. (2012). Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non–small-cell lung cancer: a phase III trial. Journal of clinical oncology, 30(17), 2070-2078.
Related Products
MARKETER DETAILS
cipla pharma
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.